Artificial intelligence is accelerating clinical development by enabling smarter trial design, faster patient identification, and real‑time data insights. Across discovery and preclinical stages, AI reduces early risk by improving target selection and translational confidence. In the clinic, AI supports precision recruitment, adaptive protocols, and proactive trial monitoring—helping sponsors shorten timelines, reduce costs, and increase probability of success from first‑in‑human through late‑stage development.
Tuesday, May 5, 12:50 - 13:20, room Rio, level 2
Clinilabs is a global, full-service contract research organization (CRO) focused exclusively on supporting pharmaceutical, biotechnology, and device organizations of all sizes in central nervous system (CNS) drug, device, and technology development around the world. Drawing on deep, indication-level expertise, a proven process, the latest technology, and global reach spanning North America, Europe, and beyond, we expertly manage Phase 1-3 trials to accelerate treatments for a range of psychiatric, neurological, and substance use disorders, as well as rare and ultra-rare CNS disorders.
